U.S. Cognitive Assessment and Training in Healthcare Market Size, Share & Industry Analysis, By Assessment Type (Pen and Paper, Biometrics, and Hosted), By Application (Screening and Diagnostics, Clinical Trials, Brain Training, and Others), and Country Forecast, 2024-2032

The U.S. cognitive assessment and training in healthcare market size was worth USD 2.28 billion in 2023 and is projected to grow at a CAGR of 19.1% during the forecast period.

Cognitive impairment is the term used for individuals facing challenges in normal mental functioning, including communication, social, and self-help skills. Cognitive tests are used to assess the brain's normal functioning and are also used for training individuals suffering from cognitive impairment. The increasing prevalence of cognitive impairment and dementia in the country has been fueling the U.S. cognitive assessment and training in healthcare market share expansion.

• For instance, as per the Alzheimer's Association, in 2023, around 6.7 million Americans aged 65 or older are living with Alzheimer’s disease. Out of this number, around 73% of the population is aged 75 or above.

Moreover, cognitive assessment has its application in clinical studies to assess the cognitive functioning of the recruited patients. Therefore, the increasing adoption of cognitive assessment in clinical trials has also been fueling the U.S. cognitive assessment and training in healthcare market growth.

During the COVID-19 outbreak in 2020, the market grew significantly. This was due to the increased use of cognitive assessment and training in healthcare for the cognitive monitoring of COVID-19-infected patients.

LATEST TRENDS

Adoption of Digital Technologies in the U.S. has been Increasing Post COVID-19 Outbreak

Traditional methods of assessment and training, such as pen and paper-based assessments, have been adopted and practiced over a period of time. However, after the sudden outbreak of COVID-19, patients visiting the clinic for cognitive assessment were reduced to control the spread of the virus. This resulted in adopting digital technologies to conduct cognitive assessments and training in healthcare.

The adoption of digital cognitive assessment tools, such as Computer Assessment of Mild Cognitive Impairment (CAMCI), Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment (CANS-MCI), and others, by healthcare providers increased post-COVID-19 outbreak. Moreover, the market players have also increased their focus on launching digital cognitive assessment and training in healthcare to fasten the assessment procedure. 

• For instance, in November 2022, Neurotrack Technologies, Inc. launched a three-minute digital cognitive assessment. This assessment enables quick screening for cognitive decline and impairment among the patients. With this launch, the company aimed to increase the annual number of completed cognitive assessments.

DRIVING FACTORS

Increasing Demand for Cognitive Assessment during Clinical Trials has been Fueling the Demand for these Tools

Cognitive assessment and training in healthcare during clinical studies helps in analyzing the effects of the drug molecule being studied on the patient by assessing their cognitive function.

• For instance, as per the data published by National Centre for Biotechnology Information (NCBI), in 2022, 50,575 patients were enrolled in 172 clinical studies to study the efficacy of drug candidates for Alzheimer’s disease. Cognitive assessments of these patients were conducted regularly to monitor their cognitive functioning.

Cognitive assessment helps analyze the drug candidate's effect on the patient during clinical trials. Therefore, the increasing number of clinical trials in the country has been fueling the adoption of cognitive assessment in research studies.

• For instance, in 2022, around 1,662 clinical trials were registered for neuropsychiatric conditions, experiencing a growth of 19.6% in the registered clinical trials from 2016.

The increasing number of clinical studies involving cognitive assessment has been fueling the U.S. market growth.  

Request a Free sample to learn more about this report.

In 2020, 5.8 million people aged 65 and older were suffering from Alzheimer's disease in the U.S. However, in 2023, around 6.7 million Americans aged 65 and older are suffering from the disease, experiencing an increase of 15.5% from 2020.

RESTRAINING FACTORS

Limitations Associated with the Use of Digital Cognitive Assessment is Negatively Impacting the Market Growth

The rising prevalence of cognitive impairment and increasing adoption of solutions for assessment in clinical studies have been fueling the market growth. However, certain limitations associated with the use of cognitive assessment and training in healthcare have been limiting their adoption. One major factor is the high cost of digital cognitive assessment. For instance, a subscription to CogniFit Inc. software for researchers and clinicians can cost around USD 2,999 annually or USD 299 monthly.

Moreover, with the increasing demand for effective cognitive assessment and training in healthcare settings, market players have increased their focus on developing technologically advanced solutions and services for cognitive assessment and training in healthcare. However, regulatory approval and commercialization of these solutions can take longer. The high cost of digital cognitive assessment and stringent regulatory policies limits the penetration of digital technologies in cognitive assessment and training, thereby limiting the market growth.

SEGMENTATION

By Assessment Type Analysis

Based on assessment type, the market is fragmented into pen and paper, biometrics, and hosted.

The pen and paper segment dominated the market in 2022. The pen and paper-based neurocognitive testing is being traditionally practiced to assess various cognitive disorders such as traumatic brain injury, dementia, and others. The increasing prevalence of these disorders has been fueling the segment’s growth.

• For instance, as per the study by Columbia University in October 2022, 10% of Americans aged 65 and older had dementia. Moreover, 22% of Americans of the same age suffered mild cognitive impairment.

By Application Analysis

On the basis of application, the market is divided into screening and diagnostics, clinical trials, brain training, and others.

The clinical trials segment dominated the U.S. market in 2022. The segment's dominance is attributed to the market players’ focus on enhancement of its software to expand its offerings in clinical trial management.

• For instance, in July 2023, Signant Health relaunched its SmartSignals Supplies software as SmartSignals Supplies GxP Inventory with expanded capabilities. Through this enhanced platform, the company aims to provide its services to small and mid-sized companies for clinical research.

KEY INDUSTRY PLAYERS

Major players, such as Cambridge Cognition Ltd, CogniFit Inc., and Cogstate Ltd, account for a significant portion of the U.S. market share. The strong presence of these companies is attributed to their focus on collaborations and partnerships to strengthen their position in the market.

• For instance, in October 2022, Cambridge Cognition Ltd. acquired eClinicalHealth. This acquisition enhanced the company’s virtual clinical trial offerings.

Other players in the market include CNS Vital Signs LLC and Signant Health. These companies have increased their focus on the adoption of advanced technologies to enhance their service offerings in the market.

LIST OF KEY COMPANIES PROFILED:

• Cambridge Cognition Ltd (U.K.)


• CogniFit Inc. (U.S.)


• Cogstate Ltd. (Australia)


• CNS Vital Signs LLC. (U.S.)


• WIRB-Copernicus Group (U.S.)


• Signant Health (U.S.)


• Posit Science (U.S.)


• Clario (U.S.)


• Cognetivity Neurosciences (Canada)

KEY INDUSTRY DEVELOPMENTS:

• October 2022 – Cambridge Cognition Ltd. acquired eClinicalHealth Ltd, a full-service digital technology provider, to enhance its product portfolio.


• June 2022 – Cogstate Ltd. joined the Digital Medicine Society’s (DiMe) Alzheimer’s disease and Related Dementias (ADRD) Digital Measures Development Project. With this initiative, the company strengthened its brand presence.


• May 2022 – Clario expanded its partnership with Cogstate LTD. to provide data quality solutions for neuroscience assessments in therapeutic development. This partnership enhanced the company’s service offerings.

REPORT COVERAGE

To gain extensive insights into the market, Request for Customization

The U.S. cognitive assessment and training in healthcare market research report provides a detailed analysis of the market. The report includes market segmentation, key points such as an overview of technological advancements, and the portfolio of the key players operating in the market. Additionally, it includes key industry developments such as mergers, collaborations, & acquisitions and the impact of the COVID-19 pandemic on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation